Table 3.
Relationship between allelic loss at the TP53 gene locus and clinicopathological characteristics
| Characteristic | Informative tumours | With LOH (%) | Without LOH (%) | p Value |
| Patients (n) | 159 | 78 (49) | 81 (51) | — |
| Age (y)* | 71 (9.8) | 70.5 (9.8) | 71 (10) | — |
| Sex | ||||
| Male | 96 (60.5) | 51 (53) | 45 (47) | |
| Female | 63 (39.5) | 27 (43) | 36 (57) | 0.26 |
| Tumour side | ||||
| Right | 39 (23.9) | 20 (53) | 18 (47) | |
| Left | 60 (37.8) | 32 (53) | 28 (47) | |
| Rectum | 61 (38.3) | 26 (43) | 35 (57) | 0.44 |
| Stage | ||||
| I | 13 (7.9) | 3 (23) | 10 (77) | |
| II | 77 (48.7) | 44 (57) | 33 (43) | |
| III | 59 (36.8) | 26 (44) | 33 (56) | |
| IV | 10 (6.6) | 5 (50) | 5 (50) | 0.10 |
| Vascular invasion | ||||
| Yes | 79 (49.5) | 33 (42) | 46 (58) | |
| No | 80 (50.5) | 45 (56) | 35 (44) | 0.09 |
| Polyps | ||||
| + | 52 (32.7) | 29 (56) | 23 (44) | |
| − | 107 (67.3) | 49 (48) | 58 (52) | 0.31 |
| CEA | ||||
| 0–5 ng/ml | 76 (48.1) | 37 (49) | 39 (51) | |
| > 5 ng/ml | 28 (17.7) | 14 (50) | 14 (50) | 0.09 |
| Unknown | 55 (34.2) | 27 (49) | 28 (51) | |
| Lymph node metastases | ||||
| Negative | 98 (61.5) | 50 (51) | 48 (49) | |
| 1–3 | 41 (25.9) | 21 (51) | 20 (49) | 0.40 |
| 4 | 20 (12.6) | 7 (35) | 13 (65) | |
| Tumour differentiation | ||||
| Well | 56 (35) | 26 (46) | 30 (54) | |
| Moderate | 76 (48) | 42 (55) | 34 (45) | 0.23 |
| Poor | 27 (17) | 10 (37) | 17 (63) | |
*Values are median (SEM). All other values are number (%).
LOH, loss of heterozygosity; CEA, carcinoembryonic antigen.